Holen Sie sich die Stockscreener-App
103.63
1.75%
1.78
Handel nachbörslich:
103.58
-0.05
-0.05%
Spyre Therapeutics Inc Aktie (SYRE) Neueste Nachrichten
Wall Street Zen Downgrades Spyre Therapeutics (NASDAQ:SYRE) to Sell - marketbeat.com
Stifel Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $123 - moomoo.com
SYRE Stock Marks Best Session In About 3 Years — Here’s Why - Stocktwits
Perceptive Advisors discloses 4.9% stake in Spyre Therapeutics (SYRE) via Master Fund - Stock Titan
RTW Investments (SYRE) reports 4.8% Spyre Therapeutics stake for managed funds - Stock Titan
Dimensional Fund Advisors LP Sells 29,593 Shares of Spyre Therapeutics, Inc. $SYRE - marketbeat.com
Spyre Therapeutics, Inc. Stock 12‑Month Price Target Raised to $126.85, Implies 22% Upside - TradingView
Price to earnings forward of Spyre Therapeutics, Inc – SWB:3920 - TradingView
Price to book forward of Spyre Therapeutics, Inc – SWB:3920 - TradingView
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Expected to Rise, BTIG Research Analyst Says - marketbeat.com
SYRE Maintained by BTIG -- Price Target Raised to $132.00 - GuruFocus
Spyre Therapeutics director Jeffrey W. Albers disposes of USD 2.39 million in common shares - Bitget
Spyre Therapeutics, Inc. $SYRE Shares Bought by Bank of America Corp DE - marketbeat.com
Spyre Therapeutics Insider Sold Shares Worth $2,404,190, According to a Recent SEC Filing - marketscreener.com
Spyre Therapeutics director Albers sells $2.4m in stock By Investing.com - Investing.com India
Spyre Therapeutics director Albers sells $2.4m in stock - Investing.com India
Spyre Therapeutics (NASDAQ:SYRE) Director Sells 18,000 Shares - marketbeat.com
Spyre Therapeutics (SYRE) director logs 5,000-share option exercise and 23,000-share sale - Stock Titan
Spyre Therapeutics Launches Program, Mid-Stage Trial for Drug Combination to Treat Hidradenitis Suppurativa - marketscreener.com
Spyre Therapeutics Announces Launch Of Spy772 Program - TradingView
Spyre Therapeutics launches combination therapy trial for hidradenitis suppurativa - Investing.com
Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa - The Manila Times
Spyre Therapeutics launches combination therapy trial for hidradenitis suppurativa By Investing.com - Investing.com Canada
Spyre Therapeutics, Inc. Launches SPY772 Program And Initiates Phase 2 SKYLIGHT Trial In Hidradenitis Suppurativa - marketscreener.com
California State Teachers Retirement System Purchases 11,204 Shares of Spyre Therapeutics, Inc. $SYRE - marketbeat.com
Can Spyre Therapeutics (SYRE) Justify Its Premium After Positive Phase 2 Data? - Yahoo Finance
Price to sales forward of Spyre Therapeutics, Inc. – NASDAQ:SYRE - TradingView
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $128 - Moomoo
Spyre Therapeutics (NASDAQ:SYRE) Stock Rating Upgraded by Wall Street Zen - marketbeat.com
Spyre Therapeutics, Inc. SEC Filing (Aug 7, 2026) - Stock Titan
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Spyre Therapeutics, Inc. (SYRE) Investor Outlook: Promising Biotech with 4.98% Upside Potential - DirectorsTalk Interviews
Price to earnings forward of Spyre Therapeutics, Inc – DUS:3920 - TradingView
Spyre's CEO Sold Stock, but Kept 567,000 Shares. Here's What Long-Term Investors Should Know - The Motley Fool
A Spyre Executive Sold Stock After a 500% Run. Here's What Long-Term Investors Should Know - The Motley Fool
SPYRE THERAPEUTICS INC : RAYMOND JAMES RAISES TARGET PRICE TO $121 FROM $88 - webull.com
We Think Spyre Therapeutics (NASDAQ:SYRE) Can Easily Afford To Drive Business Growth - moomoo.com
Cameron Turtle, Spyre Therapeutics CEO, sells $1.43m in stock By Investing.com - Investing.com South Africa
Spyre CFO Scott Burrows sells $716,771 in stock By Investing.com - Investing.com Nigeria
Form 4 Spyre Therapeutics Inc For: 6 August By Investing.com - Investing.com Nigeria
Cameron Turtle, Spyre Therapeutics CEO, sells $1.43m in stock - Investing.com
A Quick Look at Today's Ratings for Spyre Therapeutics(SYRE.US), With a Forecast Between $112 to $130 - Moomoo
The Manufacturers Life Insurance Company Trims Stock Position in Spyre Therapeutics, Inc. $SYRE - MarketBeat
Spyre Therapeutics Insider Sold Shares Worth $1,432,705, According to a Recent SEC Filing - marketscreener.com
Spyre Therapeutics (SYRE) CEO Cameron Turtle Sells 15,000 Shares - GuruFocus
SPYRE THERAPEUTICS INC : LEERINK PARTNERS RAISES TARGET PRICE TO $124 FROM $106 - webull.com
Wedbush Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $130 - moomoo.com
SPYRE THERAPEUTICS, INC. : WELLS FARGO RAISES TARGET PRICE TO $115 FROM $90 - webull.com
Spyre Therapeutics (NASDAQ:SYRE) CEO Sells $1,432,650.00 in Stock - marketbeat.com
Spyre Therapeutics (SYRE) CEO trades 15,000 shares under 10b5-1 plan - Stock Titan
Spyre Therapeutics, Inc. Stock 12‑Month Price Target Raised to $119.43, Implies 14% Upside - TradingView
SYRE's Q2 Loss Narrower Than Expected, Pipeline Progresses - The Globe and Mail
Spyre Therapeutics (NASDAQ:SYRE) Price Target Raised to $130.00 at Wedbush - marketbeat.com
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Expected to Rise, Guggenheim Analyst Says - marketbeat.com
Wedbush Adjusts Price Target on Spyre Therapeutics to $130 From $100, Maintains Outperform Rating - moomoo.com
SYRE SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Spyre Therapeutics stock hits 52-week high at 105.11 USD By Investing.com - Investing.com South Africa
Spyre Therapeutics stock hits 52-week high at 105.11 USD - Investing.com
Spyre Therapeutics (NASDAQ:SYRE) Posts Quarterly Earnings Results - marketbeat.com
Spyre Therapeutics (NASDAQ:SYRE) Sets New 52-Week High Following Strong Earnings - MarketBeat
Spyre Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Spyre Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Spyre Therapeutics reports $1.145B cash, Q2 net loss $36.2M; positive Phase 2 induction data - TradingView
Spyre Therapeutics, Inc. Q2 2026: Net loss $36.2M, EPS $(0.36) — 10-Q Summary - TradingView
Spyre Therapeutics (Nasdaq: SYRE) holds $1.1B cash despite higher 2026 loss - Stock Titan
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):